Vikas Jaiswal, S. Nagpal, Christine Angela E. Labitag, J. Tayo, Abhinav Patel, K. Lo, R. Vijayan, Wanessa F. Matos, Sadia Yaqoob, Priyanka Panday, Saloni Savani, Zeinab Alnahas, Arushee Bhatnagar, Y. Diaz, J. Dylewski
{"title":"COVID - 19诱导心肌炎的系统综述——症状、预后和临床表现","authors":"Vikas Jaiswal, S. Nagpal, Christine Angela E. Labitag, J. Tayo, Abhinav Patel, K. Lo, R. Vijayan, Wanessa F. Matos, Sadia Yaqoob, Priyanka Panday, Saloni Savani, Zeinab Alnahas, Arushee Bhatnagar, Y. Diaz, J. Dylewski","doi":"10.1101/2021.05.29.21258059","DOIUrl":null,"url":null,"abstract":"Objective: With the advent of a novel coronavirus in December 2019, several case studies have reported its adversity on cardiac cells. We conducted a systematic review that describes the symptomatology, prognosis, and clinical findings of patients with COVID-19-related myocarditis. Methods: Search engines including PubMed, Google Scholar, Cochrane Central, and Web of Science were queried for SARS-CoV-2 or COVID 19 and myocarditis. PRISMA guidelines were employed, and peer-reviewed journals in English related to COVID-19 were included. Results: This systematic review included 22 studies and 37 patients. Eight patients (36%) were confirmed myocarditis, while the rest were possible myocarditis. Most patients had elevated cardiac biomarkers, including troponin, CRP, CK, CK-MB, and NT-pro BNP. Electrocardiogram results noted tachycardia (47%), left ventricular hypertrophy (50%), ST-segment alterations (41%), and T wave inversion (18%). Echocardiography presented reduced LVEF (77%), left ventricle abnormalities (34%), right ventricle aberrations (12%), and pericardial effusion (71%). Further, CMR showed reduced myocardial edema (75%), non-ischemic patterns (50%), and hypokinesis (26%). The mortality was significant at 25%. Conclusions: Mortality associated with COVID-19 myocarditis appears significant but underestimated. Further studies are warranted to evaluate and quantify patients actual prognosis and outcomes with COVID-19 myocarditis.","PeriodicalId":238598,"journal":{"name":"Cardiology & Vascular Research","volume":"9 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"A Systematic Review of COVID - 19 Induced Myocarditis - Symptomatology, Prognosis, and Clinical Findings\",\"authors\":\"Vikas Jaiswal, S. Nagpal, Christine Angela E. Labitag, J. Tayo, Abhinav Patel, K. Lo, R. Vijayan, Wanessa F. Matos, Sadia Yaqoob, Priyanka Panday, Saloni Savani, Zeinab Alnahas, Arushee Bhatnagar, Y. Diaz, J. Dylewski\",\"doi\":\"10.1101/2021.05.29.21258059\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: With the advent of a novel coronavirus in December 2019, several case studies have reported its adversity on cardiac cells. We conducted a systematic review that describes the symptomatology, prognosis, and clinical findings of patients with COVID-19-related myocarditis. Methods: Search engines including PubMed, Google Scholar, Cochrane Central, and Web of Science were queried for SARS-CoV-2 or COVID 19 and myocarditis. PRISMA guidelines were employed, and peer-reviewed journals in English related to COVID-19 were included. Results: This systematic review included 22 studies and 37 patients. Eight patients (36%) were confirmed myocarditis, while the rest were possible myocarditis. Most patients had elevated cardiac biomarkers, including troponin, CRP, CK, CK-MB, and NT-pro BNP. Electrocardiogram results noted tachycardia (47%), left ventricular hypertrophy (50%), ST-segment alterations (41%), and T wave inversion (18%). Echocardiography presented reduced LVEF (77%), left ventricle abnormalities (34%), right ventricle aberrations (12%), and pericardial effusion (71%). Further, CMR showed reduced myocardial edema (75%), non-ischemic patterns (50%), and hypokinesis (26%). The mortality was significant at 25%. Conclusions: Mortality associated with COVID-19 myocarditis appears significant but underestimated. Further studies are warranted to evaluate and quantify patients actual prognosis and outcomes with COVID-19 myocarditis.\",\"PeriodicalId\":238598,\"journal\":{\"name\":\"Cardiology & Vascular Research\",\"volume\":\"9 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiology & Vascular Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2021.05.29.21258059\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology & Vascular Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2021.05.29.21258059","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
目的:2019年12月,随着新型冠状病毒的出现,一些案例研究报道了它对心脏细胞的不利影响。我们对covid -19相关心肌炎患者的症状、预后和临床表现进行了系统回顾。方法:在PubMed、谷歌Scholar、Cochrane Central、Web of Science等搜索引擎中查询SARS-CoV-2或COVID - 19与心肌炎的相关性。采用PRISMA指南,纳入与COVID-19相关的同行评议英文期刊。结果:本系统综述包括22项研究和37例患者。确诊心肌炎8例(36%),其余为可能的心肌炎。大多数患者心脏生物标志物升高,包括肌钙蛋白、CRP、CK、CK- mb和NT-pro BNP。心电图结果显示心动过速(47%),左室肥厚(50%),st段改变(41%)和T波反转(18%)。超声心动图显示LVEF降低(77%),左心室异常(34%),右心室畸变(12%)和心包积液(71%)。此外,CMR显示心肌水肿减少(75%),非缺血模式(50%)和运动不足(26%)。死亡率高达25%。结论:与COVID-19心肌炎相关的死亡率显着但被低估。需要进一步的研究来评估和量化COVID-19心肌炎患者的实际预后和结局。
A Systematic Review of COVID - 19 Induced Myocarditis - Symptomatology, Prognosis, and Clinical Findings
Objective: With the advent of a novel coronavirus in December 2019, several case studies have reported its adversity on cardiac cells. We conducted a systematic review that describes the symptomatology, prognosis, and clinical findings of patients with COVID-19-related myocarditis. Methods: Search engines including PubMed, Google Scholar, Cochrane Central, and Web of Science were queried for SARS-CoV-2 or COVID 19 and myocarditis. PRISMA guidelines were employed, and peer-reviewed journals in English related to COVID-19 were included. Results: This systematic review included 22 studies and 37 patients. Eight patients (36%) were confirmed myocarditis, while the rest were possible myocarditis. Most patients had elevated cardiac biomarkers, including troponin, CRP, CK, CK-MB, and NT-pro BNP. Electrocardiogram results noted tachycardia (47%), left ventricular hypertrophy (50%), ST-segment alterations (41%), and T wave inversion (18%). Echocardiography presented reduced LVEF (77%), left ventricle abnormalities (34%), right ventricle aberrations (12%), and pericardial effusion (71%). Further, CMR showed reduced myocardial edema (75%), non-ischemic patterns (50%), and hypokinesis (26%). The mortality was significant at 25%. Conclusions: Mortality associated with COVID-19 myocarditis appears significant but underestimated. Further studies are warranted to evaluate and quantify patients actual prognosis and outcomes with COVID-19 myocarditis.